In 2025, M&A activity increased in terms of value both in the USA and globally, reaching the highest cumulative global deal value since 2021, even as total deal volume declined. After a slower first half of 2025 amidst tariff uncertainty and broader geopolitical risks, M&A activity accelerated in the second half of the year, with several mega-deals driving value, including Union Pacific’s USD85 billion combination with Norfolk Southern and Kimberly-Clark Corporation’s USD48.7 billion acquisition of Kenvue Inc. The year 2025 also marked record private equity activity levels in the USA, driven by the availability of over USD1 trillion in dry powder, a narrowing valuation gap, and interest rate cuts.
The USA retained its position as the world’s dominant M&A market by a considerable margin, accounting for more than half of total global deal value in 2025, against a backdrop of geopolitical tensions, market volatility and unpredictable shifts in tariff, regulatory and other policy settings. Looking ahead, M&A momentum is expected to carry into 2026, supported by the continued AI boom, deregulation and renewed appetite for large-scale transactions – though geopolitical, economic and political uncertainty persist.
The last year was marked by a more favourable interest rate and flexible financing environment, a decisive shift towards M&A mega-deals and a narrowing of the valuation gap – with geopolitical tensions continuing to challenge deal-making certainty.
Deal timelines have lengthened steadily in recent years, a trend that is particularly pronounced for mega-deals. On the front end, due diligence periods have extended as buyers subject targets to increasingly rigorous scrutiny. On the back end, the period between signing and closing has remained prolonged, driven largely by regulatory review of deals raising antitrust and/or foreign investment concerns. Antitrust enforcement in particular remains robust under the new leadership of the Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division, especially across consumer-facing sectors. That said, new agency leadership has also “reversed course” by demonstrating a renewed willingness to resolve competitive concerns through negotiated settlements, which may improve sentiment around deal certainty. Against this backdrop, parties continue to focus on three key considerations:
In recent months, several state attorneys general have begun to take a more active role in merger enforcement – in some cases moving to challenge transactions previously approved by the federal agencies subject to negotiated settlement. This trend, combined with parallel HSR filing requirements implemented by numerous states (so-called “mini-HSR” legislation), means that state antitrust enforcers can no longer be discounted in the deal-making process.
On the foreign investment front, the number of transactions reviewed by the Committee on Foreign Investment in the United States (CFIUS) continued to decline in calendar year 2024 (the most recent year for which data is available), most likely reflecting a decline in voluntary CFIUS filings.
In 2025, technology M&A significantly surged, with AI driving deals across the technology, energy and infrastructure sectors, and with telecommunications, healthcare (including pharmaceuticals) and financial services being among the leading M&A sectors in the USA. Expectations are that the leading sectors will continue to be technology (particularly around AI and machine learning), energy (especially renewables) and healthcare.
A stock purchase, asset purchase, merger or tender offer are the common transaction structures that can be used to acquire a US company.
Acquisitions of Private Companies
An acquisition of a private company is often structured as a stock or asset purchase, but may need to be structured as a merger transaction if the company has a larger number of shareholders.
Stock purchases
A stock purchase is a typical method for acquiring all or part of a private company, or a division of a private company whose business is conducted through a subsidiary, where the buyer will purchase the stock of a target company from the seller shareholder(s). To acquire all of the target’s stock, all shareholder(s) need to be party to the transaction pursuant to a stock purchase agreement.
Asset purchases
An asset purchase is often used to acquire select assets or a division of a target company where the buyer will purchase identified assets and assume identified liabilities of the target company pursuant to an asset purchase agreement. The asset purchase structure allows parties to exclude specific assets and liabilities, which is a key negotiation point in an asset purchase deal.
Acquisitions of Public Companies
The most common means of acquiring a US public company are via a merger and/or tender offer.
One-step merger
A merger is a combination of two entities by operation of law, in accordance with the statutory corporate law of the states of the constituent entities, and pursuant to a merger agreement that sets forth the terms and conditions of the acquisition; it is approved by the boards of directors of the target and acquirer and then subsequently adopted by the target’s shareholders (generally by the holders of a majority of the outstanding shares) at a shareholders’ meeting. A merger is a single-step transaction, whereby, pursuant to operation of law, all of the shares of the target company are converted into the right to receive the merger consideration (which may be cash, securities or other property).
Tender offer
A tender offer is a direct offer to the shareholders of the target company to purchase their shares. Therefore, it is highly likely that not all of the shareholders of the target will tender their shares into the tender offer. For a bidder to acquire all of the shares of the target, a tender offer is inevitably a multi-step transaction, whereby, following the initial purchase of shares in the tender offer meeting a requisite threshold, the remaining shareholders of the target have to be “squeezed out” through a second-step statutory merger.
Because a tender offer is an offer made directly to the shareholders, no board of directors’ approval from the target company is technically required, although most friendly tender offers are made pursuant to a board-approved merger agreement. Most hostile transactions involve a tender offer because the acquirer can bypass the target’s board of directors and management. In any event, the board of directors of the target company will be required under other rules of the Securities and Exchange Commission (SEC) to state its position on the tender offer.
The state law of the target company’s jurisdiction of incorporation will govern many aspects of an acquisition, including substantive requirements of fairness on the transaction and provision of target company anti-takeover defences, such as the ability to implement shareholder rights plans (ie, “poison pills”). In contrast, US federal law relating to acquisitions is generally part of the US securities laws and regulations and is mostly focused on adequacy of disclosure relating to the proposed transaction, the tender offer process or proxy solicitations. Federal securities laws applicable to public companies and the sale and purchase of securities are administered and enforced by the SEC; alleged violations of state corporate law are typically challenged by private plaintiffs in state courts (private plaintiffs also often challenge violations of federal securities laws in federal courts). State securities (aka “blue sky”) laws may also be applicable depending on the relevant state. If a US publicly traded entity is involved in the transaction, stock exchange rules may also be applicable.
US federal antitrust laws are primarily enforced by the Antitrust Division of the DOJ and by the FTC. US foreign investment controls are implemented by the various agencies discussed in 2.6 National Security Review as well as other federal agencies responsible for sectoral controls.
Depending on the industries (eg, energy) and jurisdictions in which the target and acquirer operate, other filings and approvals from state and federal regulatory authorities may be required.
There are several sectors (eg, airlines, shipping between US ports and broadcast communications) in which the US government restricts foreign ownership or attaches special regulatory requirements for foreign owners. In some cases, a distinction may be made between foreign ownership by private sector and government entities. Waivers or licences allowing foreign owners to exceed standard limits are sometimes available. There are also transactions in which foreign ownership is not limited but is subject to regulatory requirements. The US government also has four separate national security-based processes for regulating inbound foreign investment and a programme for regulating certain outbound foreign investments. See 2.6 National Security Review for more details.
In the United States, the main antitrust regulations applicable to business combinations are (each as amended):
The HSR Act prescribes a pre-merger notification procedure for certain business combinations, while the Sherman and FTC Acts prohibit certain anti-competitive conduct; the Clayton Act prohibits anti-competitive transactions, among other things.
The HSR Act requires that the parties to proposed stock or asset transactions file pre-merger notification notifications with the FTC and DOJ and observe a waiting period (usually 30 calendar days; 15 calendar days for cash tender offers and transactions in bankruptcy) if the transaction exceeds certain thresholds. This initial waiting period allows federal antitrust authorities to investigate the transaction prior to its consummation on the basis of the filing. If the government declines to take enforcement action concerning the acquisition, the parties may close from a US antitrust perspective within one year once the waiting period expires. Otherwise, the government may act before the initial period expires by issuing a “Second Request”, although the acquirer may choose to “pull and refile” its notification to effectively grant the government an additional 30 or 15 days, as the case may be, to review the transaction without issuing a Second Request.
A Second Request will extend the waiting period and requires the parties to submit a wide range of documents and answer numerous interrogatories. After the parties have substantially complied with these requests, a second 30-calendar day (or ten-calendar day for cash tender offers and transactions in bankruptcy) waiting period begins. There is a one-year deadline within which to substantially comply with the Second Request, and parties receiving a Second Request cannot close before the second waiting period expires. The antitrust agencies typically seek a timing agreement with the parties that obligates the parties to provide several weeks’ notice of substantial compliance and closing.
If the government still has substantive concerns about the transaction at the end of this period and has not reached agreement with the parties on an appropriate remedy, it can seek to enjoin the closing of the transaction in federal district court. In the absence of an injunction, parties may close the deal, subject to any applicable timing agreement.
Employee benefit and executive compensation-related issues, implicating federal, state and local laws, have been known to unravel M&A transactions. Sellers may reduce risks and streamline negotiations through proactive pre-sale planning. On the other hand, buyers may be able to maximise their deal-related protections and their post-closing alternatives by ensuring early-stage attention to the matters discussed below.
Employment
Employment arrangements in the United States are generally “at will”. Buyers need to consider worker classification and proper visa status of workers. Buyers should be aware of the Worker Adjustment and Retraining Notification (WARN) Act and similar state laws that may give employees the right to early notice of impending lay-offs or plant closings (or salary in lieu of notice).
Both buyers and sellers need to assess whether key employees have a right to resign with full severance on a change in control and whether such employees are subject to post-employment restrictive covenants. Generally, employment-related covenants and agreements should be reviewed to determine whether they are adequate and assignable to the buyer (or surviving entity). The enforceability of such agreements is determined on a state-by-state basis as certain states have restricted or banned the use of non-competes.
Equity plans and award agreements
Buyers need to review employee equity plans and the impact of a change of control on outstanding employee equity. Numerous considerations go into determining treatment of equity awards in a deal, including:
Non-qualified deferred compensation plans
Key issues for the buyer to consider include:
Employee benefits
Buyers should be aware of the Employee Retirement Income Security Act (ERISA), which governs the operation and terms of certain employee benefit plans, including their treatment in connection with transactions.
Retirement plans
There has been an avalanche of litigation surrounding excessive fees, poorly monitored investments and claims related to employer stock investments in 401(k) plans. Additionally, compliance problems in need of correction and their impact on a possible plan termination or plan merger may need to be assessed. Buyers and sellers need to also determine whether any plans of buyer and seller should be terminated prior to a change of control.
If a seller maintains a defined benefit plan, actuarial assistance may be needed to understand the funded position of such plans and whether the actuarial assumptions used are reasonable. Often, the Pension Benefit Guarantee Corporation may insert themselves into the M&A process if either the buyer or seller has a significantly underfunded pension plan.
If the buyer has a collectively bargained workforce, attention will be needed to understand whether the buyer participates in multi-employer pension plans sponsored by a union, and whether the structure of the transaction will result in a withdrawal under the plan and withdrawal liability.
Health plans
The buyer would need to know whether the health plans are self-insured and whether they maintain adequate stop-loss coverage. The parties must also understand their obligations under the Consolidated Omnibus Budget Reconciliation Act (COBRA) and similar state laws that provide benefit continuation coverage after termination of employment. Certain states may also require the payout of accrued leave or other benefits. Additionally, the buyer must also consider:
Golden Parachute Excise Taxes
Section 280G of the Code regulates “golden parachute” payments made to certain key employees in M&A transactions. If Section 280G is triggered, excise taxes may be imposed on key executives at the company and the company may lose corporate deductions, so early analysis will be critical.
There are generally four different US bodies responsible for addressing national security concerns that could arise from inbound foreign investments:
An Outbound Investment Security Program (OISP) applicable to outbound foreign investments is also in place. A single transaction can implicate more than one regime.
CFIUS is a multi-agency panel charged with identifying and addressing national security risks arising from a wide variety of foreign investments in US businesses and certain transactions involving US real estate. The CFIUS process normally involves a joint filing by the parties to a transaction, typically followed by additional questions from CFIUS. CFIUS has jurisdiction over any acquisition of control of a US business (often including US activities of a non-US parent) and also has jurisdiction over certain non-controlling investments in companies involved with critical technologies, critical infrastructure or sensitive personal data (“TID Businesses”). Investments in TID Businesses can sometimes be subject to mandatory pre-closing CFIUS filings.
CFIUS’ jurisdiction over a transaction is perpetual, and CFIUS will have the right to call in the transaction for review at any time before or after closing. On the other hand, CFIUS offers a “safe harbour” against further review if it has cleared an acquisition of control or a non-controlling investment (though in the latter case incremental acquisitions that increase the investor’s rights can be subject to a new CFIUS case).
The DCSA is an element of the US Department of Defense, responsible for mitigating foreign ownership, control or influence (FOCI) of government contractors and subcontractors.
Traditionally, FOCI mitigation was limited to US businesses that hold facility security clearances. In 2024, the DCSA began selectively mitigating FOCI of certain US government contractors and subcontractors that do not hold facility security clearances but are otherwise engaged in activities the DCSA deems sensitive. The DCSA does not approve transactions, but failure to receive FOCI mitigation could lead to the DCSA terminating the contractor’s facility clearance, disabling its ability to continue performing on sensitive contracts.
The DDTC regulates foreign ownership or control of manufacturers, service providers, exporters and brokers whose activities are governed by the International Traffic in Arms Regulations (ITAR), a set of export controls governing military goods and services. The DDTC requires pre- and post-closing notifications of new or changed foreign ownership or control of ITAR registrants, mainly to confirm that foreign investors or other foreign parties are not improperly afforded access to ITAR-controlled technology. Like the DCSA, the DDTC cannot block a transaction, but non-compliance with ITAR compliance can cause revocation of a company’s registration.
Team Telecom is a multi-agency panel led by the Departments of Justice, Homeland Security and Defense, which conducts national security- and law enforcement-related reviews of foreign applications for certain telecommunications licences granted by the Federal Communications Commission (FCC). Team Telecom can recommend that the FCC deny (or in some cases terminate) a licence or place conditions on the granting or transfer of ownership of a licence.
The OISP, which took effect on 2 January 2025 following a 2023 executive order and is managed by the Department of the Treasury, either prohibits or requires notification of US-led investments directly or indirectly supporting certain activities by entities in or controlled from China that relate to semiconductors and microelectronics, quantum computing or AI. The scope of the regulations is broad, and can include non-US investors in which US persons are participating in making the investment decisions and non-Chinese investment targets that have substantial affiliated operations in China. The Comprehensive Outbound Investment National Security Act of 2025 (the “COINS Act”) codified and changed the scope of the OISP but will only come into force as implementing regulations take effect.
Recent judicial decisions have clarified when Delaware courts may apply the most demanding standard of judicial review – entire fairness. However, in March 2025, the Delaware state legislature amended the Delaware General Corporation Law (DGCL) to codify certain holdings and to remove ambiguities relating to transactions involving controlling stockholders or conflicted management (the “Amendments”). In creating safe harbours for transactions involving interested directors/officers or controlling stockholders, the Amendments were passed in part to maintain and enhance Delaware’s reputation as the most attractive jurisdiction in which companies may seek to incorporate or reincorporate.
The Amendments:
Although the Amendments faced constitutional challenge, the Delaware Supreme Court ultimately upheld their constitutionality in an opinion issued on 27 February 2026.
Significant changes to the pre-merger notification form under the HSR Act took effect on 10 February 2025. The new HSR form added several filing requirements to the old form, including:
The new HSR form materially increased the time and effort it takes parties to prepare their filings. This increased burden prompted a legal challenge led by the United States Chamber of Commerce in 2025. In early February 2026, a federal district court vacated the new HSR form on the basis that it is disproportionately burdensome, arbitrary and capricious, thereby violating the Administrative Procedures Act. On 19 March 2026, the US Court of Appeals for the Fifth Circuit denied the Federal Trade Commission’s motion for a stay pending appeal, rendering the district court’s judgment vacating the new HSR form effective immediately. Accordingly, the agencies are now accepting HSR filings using the form and instructions that were in place before 10 February 2025, the effective date of the new HSR form (although parties may still file under the 2025 version – ie, the “new HSR form” – voluntarily). While the agencies’ appeal to the Fifth Circuit is pending, the Commission and DOJ have published a request for public comment regarding the effectiveness of the HSR pre-merger reporting requirements, indicating that the agencies may be considering drafting revisions to the HSR form and instructions in line with the district court’s opinion.
With respect to outbound investment, the COINS Act, enacted in December 2025, codified and changed the scope of the OISP but will only come into force as implementing regulations take effect – a process that should be completed by the first quarter of 2027.
Stakebuilding is permitted in the United States and, in contrast to many other jurisdictions’ takeover laws, US federal law does not mandate that an acquirer make a bid for the target upon reaching a specified threshold. Therefore, unless it has publicly announced or commences a tender offer for shares of the target, an acquirer may purchase a publicly traded target’s shares on the open market, so long as the acquirer does not violate insider trading rules. US securities laws do generally require an acquirer to file a notification on Schedule 13D (or a short-form equivalent) upon crossing a 5% beneficial ownership threshold, as described in 4.2 Material Shareholding Disclosure Threshold. Additionally, acquisitions in excess of the HSR Act threshold (USD133.9 million as of February 2026) will require an antitrust filing.
Furthermore, a number of states, including Delaware, have “anti-takeover” statutes that have the effect of encouraging acquirers to negotiate with management and discourage certain hostile activities. For example, Delaware’s business combination statute prevents acquirers from entering into business combinations with a target if they have exceeded a specific ownership threshold (15%) unless they received prior board of directors’ approval or a super-majority vote of the stockholders.
Some sectoral regulatory approvals and national security controls on foreign investment may also be triggered by ownership thresholds.
Under Sections 13(d) and 13(g) of the US Securities Exchange Act of 1934 (the “Exchange Act”), persons or groups who own or acquire beneficial ownership of more than 5% of certain classes of equity securities registered under the Exchange Act are required to file beneficial ownership reports with the SEC. Generally, if Section 13(d) is triggered, a person must file a Schedule 13D unless they are eligible to use Schedule 13G. Schedule 13G, a shorter form requiring less disclosure, is available to passive investors meeting certain requirements.
A beneficial owner of a security includes any person who, directly or indirectly, has or shares either:
A Schedule 13D must be filed five business days after acquiring beneficial ownership of more than 5% or losing Schedule 13G eligibility, and Schedule 13D amendments must be filed within two business days after the triggering event.
US public companies cannot introduce higher ownership reporting thresholds and generally would not introduce lower reporting thresholds than those mandated by federal securities laws. However, a target’s board of directors can implement certain obstacles to stakebuilding tied to ownership thresholds, such as adopting a shareholder rights plan (ie, a “poison pill”); see 9.3 Common Defensive Measures.
Dealings in derivatives are allowed in the United States, subject to applicable insider trading restrictions.
Historically, holding derivatives that, by their terms, only provide the holder with economic exposure to a covered class of security has not been considered sufficient to constitute beneficial ownership and requiring disclosure under Regulation 13D-G. A person is deemed a beneficial owner of an equity security if the person:
If such a right originates in a derivative security that is nominally “cash-settled” or from an understanding in connection with that derivative security, the holder of such cash-settled derivative security may be deemed a beneficial owner.
Aspects of a derivative instrument, including if they carry the current right to vote for directors, can determine whether acquisition of derivatives would be reportable under the HSR Act.
Shareholders must disclose beneficial ownership of more than 5% of the outstanding shares of a class of US public company equity voting securities pursuant to a Schedule 13D filing, as discussed in 4.2 Material Shareholding Disclosure Threshold. Shareholders that are required to make pre-merger notifications under the HSR Act, or certain shareholders and indirect investors with more than nominal interests in entities filing with CFIUS or other US national security review regimes, should also expect to address questions regarding the purpose of their acquisition and intentions regarding their interests in the target.
Under US federal securities laws, entry into a material definitive transaction agreement requires disclosure by public companies. Prior to signing the transaction agreement, a disclosure obligation can still exist for non-public information relating to a merger or acquisition if:
The US Supreme Court has rejected the idea that merger negotiations are only material when the parties have agreed in principle to the price and structure of the transaction. The materiality of contingent or speculative events such as M&A is determined on a case-by-case basis. There are situations where the companies involved in negotiations may remain silent as long as they do not release false or misleading information.
Ultimately, the materiality of negotiations is still determined by weighing the magnitude against the probability of the event, with additional consideration to the sensitivity of the information and the business’s purpose compared to the substantial impact on investors of a potential merger or acquisition. In practice, the determination of whether to disclose negotiations often turns on the probability that the transaction will occur. While there is no bright line test which makes the event more probable than not (short of an agreement in principle), key events that a court may consider in determining whether a disclosure obligation exists include adoption of board resolutions, execution of a letter of intent, and appointment of financial and other advisers.
Stock exchange disclosure and reporting rules and regulations governing disclosure of material non-public information also need to be considered in the M&A context.
See 7.1 Making a Bid Public.
In the USA, the buyer will generally carry out legal, financial, commercial and tax due diligence. The scope of due diligence review varies based on:
Information collected during the due diligence process can have an impact on:
US market practice does not provide for the target company preparing vendor due diligence reports for potential buyers.
If a target shareholder is to receive shares of buyer stock as consideration, reverse due diligence of the buyer would also be expected.
Standstill provisions are commonly included in confidentiality agreements if the target company is a public company, prohibiting a buyer from taking certain unsolicited actions with respect to a seller (eg, acquiring securities, commencing a tender offer or otherwise trying to obtain control of the target company or its board or management without approval).
Potential buyers also often request that the target company enter into an exclusivity agreement providing for a period of exclusive negotiations following the end of an initial bidding phase. Negotiation dynamics will influence whether a seller would agree to such a request.
As noted previously, friendly transactions are almost always effected pursuant to a board-approved merger agreement setting out the terms and conditions of the transaction between the acquirer and the target company, including whether the transaction is structured as a tender offer followed by a second-step merger.
The following factors, among others, determine how long the process of acquiring or selling a business in the United States takes:
The entire process (until closing) generally takes at minimum three to four months from when discussions are initiated.
Auctions
To maximise the sale price, sellers often run an auction process where they give potential buyers a confidential information memorandum, and the potential buyers submit their initial indications of interest several weeks (approximately three to four) thereafter. Potential buyers then normally submit their markup of the auction draft as part of their final bid, typically four to eight weeks after the initial indications of interest. Signing of the transaction agreement generally follows shortly after the seller’s receipt of the final bids and selection of the winning bidder.
Antitrust Waiting Period
See 2.4 Antitrust Regulations.
Long-Form (One-Step) Mergers
Where the target is a publicly traded company and the transaction is effected through a one-step merger (see 2.1 Acquiring a Company), to solicit the required shareholder vote, the target must prepare and file a detailed “proxy statement” with the SEC that complies with the SEC’s proxy rules. It typically takes up to two weeks to draft and file the initial proxy statement. The proxy statement may not be disseminated to shareholders until the SEC staff has commented on it and all such comments have been resolved, which may take several additional weeks.
Upon finalisation, the target then mails the proxy statement to its shareholders and files the final version with the SEC. State law, the target’s constitutional documents and rules of the applicable stock exchange will dictate the minimum length of time between the mailing of the proxy materials and the date of the target company shareholders’ meeting to approve the merger, though it is typically 20 business days.
Assuming shareholder approval, the acquirer can then complete the merger rather quickly. Typically, such transactions close on the day that the shareholders approve the transaction or on the following day.
Tender Offer
Generally, a cash tender offer (see 2.1 Acquiring a Company) takes only 30 to 60 days to close after the time that the definitive documents are executed; see 5.5 Definitive Agreements. However, the timeline for any tender offer or one-step mergers may be significantly impacted by regulatory clearances – eg, antitrust and CFIUS.
US federal securities laws and Delaware law applicable to tender offers do not require an acquirer that obtains a given threshold of the target company’s shares to make an offer for the remaining shares of the target company; see 4. Stakebuilding. However, a few states – eg, Pennsylvania – have adopted “control share cash-out” statutes, whereby once an acquirer obtains control (ie, exceeds a certain threshold of voting power) the other target company shareholders may make a demand on the acquirer to purchase their shares at a fair price.
When acquiring a company that is publicly traded in the United States, the proposed offer may be in the form of an exchange offer (ie, equity share offer), a cash offer or a combination of the two. Where the bidder is a private company or is not publicly traded in the USA – for a majority of acquisitions of US publicly traded companies – the consideration included in the bid is entirely cash.
Where there is a significant gap regarding valuation of the target company or in a deal environment or industry with high valuation uncertainty, parties may structure the purchase price such that they pay a lower price for the target company upfront but then make certain specified additional earn-out payments when certain business milestones are attained. These milestones may be tied to sales, revenue or, in certain industries such as biotech, regulatory approval of products developed or owned by the target. Alternatively, the acquirer may offer some of its stock as part of the consideration (in combination with cash) so that target company shareholders pre-acquisition can indirectly benefit from the post-acquisition success of the target company.
Generally, tender offers will be conditioned on:
In addition to the foregoing, a hostile tender offer will often require:
However, the conditions must:
Generally, tender offers are conditioned on the target company’s shareholders tendering a certain minimum number of shares – usually a number of shares sufficient to approve the subsequent merger to squeeze out the remaining shareholders; see 6.10 Squeeze-Out Mechanisms. The specific percentage required is based on state law and the target’s governing documents, but is usually at least 50% of the shares plus one additional share.
It is now rare for a transaction to have a standalone financing condition precedent (CP), whereby an acquirer will not be required to close the transaction if it is unable to raise financing between signing and closing. To mitigate financing risk, parties now typically negotiate respective covenants in terms of consummating the financing (or, on the part of the seller, to co-operate with the financing process) and provide for termination rights and/or reverse termination fees payable by the buyer upon a financing failure. A target can also expect to receive evidence of committed debt financing for the buyer at signing, and to have the ability to seek specific performance or other equitable remedy to enforce the buyer’s obligation to close the transaction if debt financing has been funded and other CPs have been satisfied.
In the United States, the parties to the transaction may agree to a variety of “deal-protection” terms. While the target and acquirer need to negotiate such terms on a case-by-case basis, some common terms in the US market are discussed below.
See also 6.11 Irrevocable Commitments.
While the above mechanisms can help safeguard the success of an acquisition, state law imposes fiduciary duties on any target company’s board of directors, which can limit the use of certain deal-protection terms and make it virtually impossible to “lock in” a transaction.
Generally, unless the deal is signed and closed simultaneously, the transaction will involve interim operating covenants for the period between signing and closing. Interim operating covenants require the target to maintain the target business between signing and closing and to deliver it at closing without material impairment.
Generally, a large shareholder will seek governance rights and other protections of its stock in a company – eg, designation right to the board of directors and a consent right to changes to the target’s governing documents or material business transactions.
The bidder may also seek information rights – eg, appointing a non-voting board observer or requiring periodic financial information and reports about the company’s operations.
The bidder may also look to obtain certain rights allowing it to exit its investment – eg, requiring registration rights for the bidder’s shares or a drag-along provision allowing it to compel other shareholders to join a sale of the company’s shares.
Voting by proxy is generally allowed under state law, federal regulations and rules of applicable US stock exchanges. The majority of shareholders of public corporations vote by proxy.
State law and the target company’s governance documents will generally set out requirements relating to:
SEC rules and regulations promulgated under the Exchange Act govern proxy solicitation of shareholders of publicly traded companies. These regulations provide additional procedural requirements and require certain information to be included in the proxy statement sent to shareholders as part of the proxy solicitation.
Lastly, the exchange on which the target company’s stock is traded (eg, the New York Stock Exchange (NYSE) or the Nasdaq Stock Market (Nasdaq)) may impose additional timing and disclosure requirements. While the exchanges may require that certain nominees be able to vote on behalf of the beneficial holders of the stock, both the NYSE and Nasdaq prohibit such voting for non-routine matters (eg, M&A) without specific instructions from the beneficial holders.
In Delaware, a squeeze-out in the form of an intermediate form merger can be effected without obtaining stockholder approval following successful completion of a tender offer for at least a majority of the outstanding shares, provided the merger meets certain procedural conditions pursuant to Section 251(h) of the DGCL. Otherwise, 90% is the most typical threshold for short-form mergers and is the threshold set by New York and for squeeze-outs in Delaware, except following a tender offer as described in the foregoing sentence. In a friendly transaction, a “top-up” stock option may be granted by the target company to the acquirer pursuant to which the target company would issue up to 19.9% of its outstanding shares to help the acquirer reach the short-form squeeze-out threshold. See 2.1 Acquiring a Company.
If, upon completion of the tender offer, the acquirer owns less than the minimum amount of the target company’s shares necessary to complete a short-form merger or otherwise does not meet the requirements of DGCL Section 251(h) as mentioned above, a long-form merger following the tender offer would be subject to shareholder approval. Since the acquirer should own the requisite number of the target company’s shares, such approval should be assured; see 6.5 Minimum Acceptance Conditions. However, the acquirer would still need to comply with state law procedures relating to the calling of a shareholders’ meeting and SEC requirements relating to proxy statements. Regardless of whether a long-form or short-form merger is utilised, appraisal rights may apply.
Before announcing a transaction, the acquirer may wish to execute agreements with the target company’s board of directors and senior management to ensure their support of the transaction, and that they will tender any shares they own into a tender offer or vote in favour of a proposed merger. In some cases, if the target company has one or more significant shareholders, requiring such shareholders to sell their stock to the acquirer, vote their stock in favour of the merger (and against any competing transaction) and/or to tender their stock into the tender or exchange offer is an effective way to “lock up” the deal.
However, Delaware courts have struck down such lock-up agreements that absolutely preclude the target company’s shareholders from availing themselves of a more attractive subsequent offer. Further, commitments by directors will be subject to the reasonableness review in light of the directors’ duties; see discussion of Revlon under 8.3 Business Judgement Rule.
For a tender offer, the SEC rules require that the acquirer file a Schedule TO (including an offer to purchase and related documents, such as a letter of transmittal). If the deal is only for cash consideration, the Schedule TO is relatively straightforward and, assuming advance preparation, is often filed on the day of (or shortly following) the announcement of the bid for the target.
For a merger, the parties will generally jointly announce the transaction when the definitive merger agreement has been entered into between the target and the acquirer. A publicly traded target company must disclose the material terms of the transaction, in a filing made with the SEC, within four business days of entry into the definitive transaction documents. Such material terms include, among others, price, break fees and conditions precedent to closing.
To solicit a required shareholder vote for a merger, the target must prepare and file a detailed “proxy statement” with the SEC that complies with the SEC’s proxy rules. Following the SEC’s review, the target then files the final version with the SEC and mails the finalised proxy statement to its shareholders.
To offer securities to the target company shareholders as consideration for the acquisition, those securities will need to be registered under the US Securities Act of 1933 (the “Securities Act”), unless an exemption applies. A registration statement for registering the securities would include (among other information) risk factors, business descriptions, financial statements, management’s discussion and analysis of financial conditions as well as transaction-specific information that would be required in a proxy statement or a Schedule TO, as applicable.
Whether a bidder needs to produce financial statements in its disclosure documents is determined on a case-by-case basis. For example, there may be situations – eg, an all-cash offer that is not conditioned on the bidder obtaining financing – where the financial condition of the bidder may not be material to the target company’s shareholders.
In a registered exchange offer or merger in which all or a portion of the merger consideration consists of securities, financial statement issues can add significant time and expense to the process to the extent that financial statements, both of the acquired business and pro forma for the combined company, may be necessary, depending on the magnitude of the transaction to the acquirer, and the requirement that financial statements filed with the SEC be prepared in accordance with US generally accepted accounting principles (GAAP) or International Financial Reporting Standards (IFRS) as promulgated by the International Accounting Standards Board (or, failing those, with a reconciliation to GAAP).
Parties generally may omit transaction agreement schedules, exhibits or attachments that do not have material transaction terms or information that would otherwise be material to the shareholders’ investment decision, or can otherwise request confidential treatment for portions of filed transaction documents. Nonetheless, the SEC may still request that such materials be submitted to it confidentially. See 7.1 Making a Bid Public.
Directors of a Delaware corporation owe two core fiduciary duties to the corporation and to its stockholders: the duty of care and the duty of loyalty. In Delaware, the obligation of good faith underlies these two core fiduciary duties.
The duty of care requires directors to act in an informed and considered manner. Accordingly, directors must inform themselves, prior to making a business decision, of all material information reasonably available to them and, based on such information, must act with due care in discharging their duties. Generally, directors will be liable for a breach of their duty of care only if they are found to have acted with gross negligence.
The duty of loyalty requires directors to act without self-interest and in the best interests of the corporation and its stockholders. Directors must refrain from fraudulent conduct, self-dealing and actions intended to entrench themselves in office. Furthermore, directors may not take personal advantage of business opportunities at the expense of the corporation. Directors found to have breached their duty of loyalty may be subject to personal liability under Delaware law.
While Delaware’s approach to directors’ duties emphasises “the primacy of the stockholder”, some other states permit, and even require, the board to consider interests of other constituencies such as employees, customers and suppliers.
Boards of directors will sometimes establish special or ad hoc committees, comprised of independent directors, to negotiate the terms of a potential business combination. Such special committee of the board will often be formed where the majority of the directors are not independent (or are conflicted), or when a controlling shareholder stands on both sides of the potential transaction or will receive different consideration in the transaction or in any side agreement to the detriment of the other shareholders. A properly functioning special committee should select and retain its own independent advisers who are free of conflicts, and the committee must be fully informed, both regarding the terms of the transaction and in terms of diligence. To fulfil their duties, the directors on the committee must actively oversee the conduct of the transaction.
Under the “business judgement rule”, Delaware courts will presume that directors have satisfied their fiduciary duties if they have made their decisions in good faith, on the basis of a reasonable investigation and after careful consideration of all material factors reasonably available, in accordance with what they honestly believe to be the best interests of the corporation and its stockholders.
In applying the business judgement rule, Delaware courts do not measure, weigh or quantify directors’ judgements, nor will courts decide whether they are reasonable in the usual context, but instead will only consider whether a rational decision-making process has been demonstrated. However, Delaware courts will apply heightened standards of review in certain contexts, as noted below.
Enhanced Scrutiny
Unocal: defensive measures
Prior to taking defensive action (see 9. Defensive Measures) against a threatened acquisition of control or takeover of the corporation, the board must – after a reasonable investigation – have reasonable grounds for believing there is a danger to corporate policy and effectiveness. Further, the directors must show that the action taken was “reasonable in relation to the threat posed”.
Revlon: sale or break-up of the company
If the board of directors authorises the sale of control or break-up of the company, the directors have a duty to seek the highest value reasonably available. This (Revlon) duty will generally be triggered if a company initiates an active bidding process seeking to sell itself or to effect a business reorganisation involving a clear break-up of the company or if, in response to a takeover proposal, a company abandons its long-term strategy and seeks an alternative transaction involving a break-up or sale of the company. If the Revlon duty is not met, the board decision will be reviewed under the more exacting standard of entire fairness (discussed below) instead of the business judgement rule.
Entire Fairness: Conflicted Transactions
The presumptions of the business judgement rule will not automatically apply to transactions involving conflicted directors or a controlling stockholder. However, Delaware law may provide for a “safe harbour” for such transactions whereby such transactions may get the benefit of business judgement rule review if the transaction is conditioned up-front on certain procedural requirements. The Amendments adopted in March 2025 codified the “safe harbour” regime, as further described below.
For conflicted director transactions, the safe harbour is available if either:
Safe harbour conditions with respect to conflicted controlling stockholder transactions would depend on the type of transaction. Generally, for such transactions (other than going-private transactions) the safe harbour is available if either:
For a controlling stockholder transaction constituting a going-private transaction, the safe harbour is available if both the Board Committee Approval and the Disinterested Stockholder Approval are received. Otherwise, the transaction may still be upheld if the interested director or controlling stockholder can demonstrate that the transaction satisfies the more demanding standard of “entire fairness” (ie, “fair dealing” and a “fair price”).
A target company board will generally engage external legal and financial advisers, and may also engage external accountants and consultants in consideration of a potential business transaction. A director can rely on such outside advisers, and consideration of robust advice from such advisers is important to demonstrating satisfaction of the director’s fiduciary duties. Target company boards generally also request a “fairness opinion” from the financial advisers on whether, from a financial standpoint, the proposed consideration is fair.
Judicial scrutiny of conflicts of interest between principals and their advisers is a point of focus, in particular when the target’s financial adviser also seeks to provide acquisition financing to the acquirer or when they may potentially favour one acquirer over another. The board of directors should educate itself on areas of potential and perceived conflicts of interest and carefully supervise and manage selection and conduct of its outside advisers.
Even though hostile tender offers are permitted in the United States, they are significantly less common than negotiated or “friendly” tender offers. Because the board is able to deploy various anti-takeover defences (see 9.3 Common Defensive Measures), even an initially unsolicited bidder may find it necessary or more advantageous to negotiate with the target company’s management to increase the likelihood of completing the transaction. Additionally, negotiated transactions are usually completed more quickly and provide for lower transaction risk for the hostile bidder, including the ability to have access to non-public due diligence materials.
Available defensive mechanisms generally encourage acquirers to negotiate with management and discourage certain hostile activities, subject to the board of directors’ fiduciary duties. Ultimately, the target company’s board of directors may remove most obstacles to an acquisition, and they may be required to do so if they believe their fiduciary duties to the target company and its shareholders so require; see 8. Duties of Directors.
Statutory Anti-Takeover Defences
State law may include certain anti-takeover provisions authorising the board to adopt certain measures that expand the board’s ability to defend against a takeover. Examples include the following.
Provisions Against Bidder Control
Additionally, the organisational documents of the target company may contain various provisions allowing a board to defend against a takeover:
Additionally, a target company may make the hostile takeover less attractive to the bidder by:
See 8.3 Business Judgement Rule.
Subject to directors’ Revlon duty (sale or break-up of the company) and other fiduciary duties (see 8. Duties of Directors), directors generally have the authority to “just say no” to a proposed business combination (but not “just say never” under certain circumstances). Although the board of directors’ use of defensive measures may be subject to heighted review, the decision to say no should likely fall within the protections of the business judgement rule; see 8.3 Business Judgement Rule.
Litigation by shareholders is very common for acquisitions of public companies in the United States; however, it is relatively uncommon for such litigation to completely derail transactions, due in part to:
Potential litigants have continued and are expected to continue to look for alternative paths in disputing M&A transactions.
Under Delaware law, stockholders who do not vote in favour of a cash merger are generally entitled to an appraisal by the Delaware Court of Chancery of the fair value of the stockholder’s shares. No appraisal rights are available if the merger consideration consists solely of shares of US-listed stock.
While appraisal actions have historically been common, recent decisions by the Delaware Supreme Court give significant weight to market-based indicators of value (eg, the target company’s stock price or the transaction price) in the absence of showing that the target’s stock trades inefficiently or that there was no robust sale process.
Litigation is usually initiated shortly (typically a matter of days) after the transaction is publicly announced. The timing is mainly driven by:
Following the COVID-19 pandemic, target companies continue to insist on certain exceptions to interim operating covenants that allow them latitude to respond appropriately to a changed business environment between signing and closing (see 6.7 Types of Deal Security Measures) and carveouts for pandemic effects in the definition of “material adverse change”.
Shareholder activism continued to be an important market force in 2025 and Q1 2026, with the majority of campaigns occurring in the USA. Certain sectors – including technology, industrials, healthcare, financial institutions, consumer, real estate, and communications and media – have seen a high concentration of activist activity in comparison to other sectors.
While M&A activism has been the primary focus of activism campaigns, especially in the second half of 2025, as activists increasingly sought to cause public companies to put themselves or discrete business divisions up for sale in response to perceived underperformance, in Q1 2026 activists shifted their focus towards board composition change and strategic and operational demands.
With increased scrutiny on companies’ M&A strategies, activists have continued to launch campaigns on pending transactions with the aim of potentially recutting deals, either with respect to the purchase price or other transaction terms.
1290 Avenue of the Americas
New York, NY 10104
United States
+1 212 903 9000
www.linklaters.com
Introduction
The pace and volume of mergers and acquisitions (M&A) transactions in the United States substantially improved in 2025 following a less robust level of activity in 2024 and a decade-low level in 2023. The return to a more robust level of activity was driven by a combination of:
Most practitioners entered 2026 with an optimistic outlook on the M&A environment in the United States, driven by the strong ending to 2025 and the expectation that the momentum would carry over into the new year. In short order, however, this optimism was tempered by uncertainty related to the impact of an evolving tariff regime, followed by the material geopolitical risks arising from the Iran conflict and its impact on the energy markets.
The Supreme Court’s decision in Learning Resources, Inc et al v Trump striking down tariffs imposed under the International Emergency Economic Powers Act provided greater clarity with respect to a portion of the tariffs imposed by the Trump administration. Any momentum resulting from the Learning Resources decisions was subsequently dampened by further escalation of the Iran conflict, ongoing shifts in tariff policies, dislocations in the private credit markets, and conflicting views of the direction of monetary policy in the United States. Market participants must test the view that private equity distribution pressure will accelerate exit activity in 2026 against the complex web of monetary policy considerations and geopolitical risks threatening to dampen any potential momentum that might arise from a wave of strategic exit transactions.
M&A Activity in 2025: A Year of Recovery
Corporate and private equity deal makers had much to celebrate at the close of 2025 as a result of a material increase in the overall volume of M&A activity, particularly with respect to the so-called mega-deals in excess of USD5 billion in value, driven in part by significant shifts in the antitrust enforcement environment in the United States. The momentum at year-end was tempered somewhat by a lower level of activity in the sub-USD500 million segment of the market, as a result of continuing challenges in monetary policy and the private credit markets as well as the related capital constraints in the middle market. The recovery in transaction volume accelerated throughout 2025, moving from a slow start in the first quarter (as market participants assessed the impact of the Trump administration’s policy priorities) to a more robust pace and volume of transactions in the third and fourth quarters of 2025.
M&A activity in the technology sector generated the highest level of transactions, driven by AI-related acquisitions, further consolidation in the cybersecurity sector, and continuing platform expansions by established technology companies. Momentum in the energy and power sector represented the second highest level of transactions in 2025, followed by healthcare and life sciences, financial services, and industrials and materials, where shifts in tariff and trade policies had a material impact as manufacturers sought to address supply chain disruptions.
M&A Activity in 2026: A Year of Uncertainty
The material impact of the conflict in Iran on the energy markets, in particular, has created a unique set of specific considerations for transaction advisers evaluating potential transactions in 2026. Volatility in energy prices impacts both valuations and transaction structures across multiple sectors and threatens to negatively impact consumer spending. The possibility of a prolonged conflict in the Middle East could result in lower corporate profits and a resulting negative impact on valuations, even in sectors where strategic and private equity buyers retain an appetite for acquisitions.
Uncertainty in valuations also increases the likelihood that contingent payment mechanisms will be more of a factor as deal makers seek to mitigate risks and bridge valuation gaps. Negotiation of earnouts and price adjustment mechanisms creates added complexity in transactions, especially when combined with material adverse change provisions, termination rights and other mechanisms that buyers utilise to address the added risks arising from the monetary policy and geopolitical risks in the current environment. There also remains the possibility that the increased level of volatility will adversely affect deal flow in certain sectors.
As in 2025, the authors remain of the opinion that deal makers willing to sort through the risks and the economic data in a highly selective manner will continue to be rewarded, especially where they demonstrate a willingness to allow sellers to share in the upside created by lower levels of actual risk and greater-than-anticipated operating profits. Scenario planning remains complex in the present environment due to the rapidly evolving policy dynamics. The prospect of gradual conflict resolution in the second quarter of 2026 creates the possibility that the second half of 2026 will give rise to an improved M&A market driven by a resilient level of profits among strategic acquirers and the appetite for liquidity in the private equity context.
Technology
The outlook for M&A in the technology sector in 2026 is broadly positive. Technology was one of the most active sectors by deal value in 2025, and the authors expect continued momentum driven by corporate demand for scale and access to emerging technologies such as artificial intelligence (AI), cloud infrastructure and cybersecurity.
AI and related infrastructure remains a central driver. Large technology companies and enterprise software providers are using acquisitions to accelerate AI adoption, obtain specialised talent and consolidate fragmented innovation ecosystems. Corporate buyers view acquisitions as a faster path to capability-building than internal development, reinforced by competitive pressures to secure computing infrastructure.
Private equity sponsors are expected to play a significant role. A large backlog of sponsor-owned portfolio companies – many held for more than five years – creates pressure for exits through strategic sales, recapitalisations or secondary buyouts. Substantial dry powder is likely to support continued investment in enterprise software, data analytics and digital infrastructure.
Despite this favourable outlook, macroeconomic volatility, geopolitical tensions, and regulatory scrutiny of large and cross-border technology transactions could moderate deal pace. The authors expect deal value to remain high but concentrated in larger, strategic transactions among well-capitalised acquirers. Overall, the technology M&A landscape in 2026 will be defined by strategic consolidation around AI and digital infrastructure, active private equity participation, and a shift towards larger, more transformative transactions.
Financial services
The outlook for M&A in the financial services sector in 2026 is generally positive, supported by strong deal momentum in 2025 and structural pressures driving consolidation across banking, asset management, insurance and fintech. Global financial services M&A value increased by approximately 25% in 2025, although deal volume rose only modestly, reflecting a shift towards larger transactions.
A principal driver is the ongoing need for scale and cost efficiency. Banks, asset managers and insurers face margin pressures from rising regulatory compliance costs, increased technology investment requirements, and competition from fintech firms, prompting acquisitions to expand distribution, reduce operating costs and diversify product offerings.
Technology transformation is also reshaping deal making. Traditional financial institutions are actively acquiring fintech companies and digital platforms to build capabilities in AI and digital payments, accelerating modernisation in response to changing consumer expectations. These technology-enabled acquisitions are expected to remain a key component of strategic financial services M&A throughout 2026.
Private equity investors are likely to remain highly active, drawn by the predictable revenue characteristics of financial services businesses. Large pools of undeployed capital and strong interest in consolidating fragmented advisory sectors – particularly wealth management and insurance distribution, where client relationships and recurring revenue models create stable cash flows – will continue to support sponsor-led activity.
Health services
In 2025, M&A activity in the health services sector remained relatively subdued amidst regulatory uncertainty and reimbursement concerns. In 2026, the authors expect both volume and value to improve, supported by stabilising interest rates, improved capital availability and renewed confidence in high-quality, cash-generating assets. Strategic buyers and private equity sponsors alike are expected to favour targeted, disciplined acquisitions that capture efficiencies and scale through technology-enabled platforms.
Regulatory and political risks remain a significant headwind. US antitrust authorities are expected to maintain heightened scrutiny of health services consolidations, including physician practice roll-ups and vertically integrated payer-provider combinations, potentially dampening appetite for larger transactions and increasing execution risk.
From a provider standpoint, investor interest will concentrate in outpatient and post-acute care, including ambulatory surgery centres, home health, hospice, behavioural health and specialty infusion services. Health services technology and software platforms will continue to attract strong interest, with AI-enabled solutions demonstrating measurable efficiency gains serving as a key driver of value. Strategic divestitures and carve-outs from health systems are also expected to generate meaningful deal flow.
Overall, 2026 should bring stronger deal value and volume relative to 2025, with the market shifting from stabilisation to acceleration, supported by resilient investor appetite and a rebalancing towards smaller, strategically aligned transactions.
Energy
In 2025, energy M&A featured lower transaction volumes but higher aggregate deal values, driven by larger, strategic transactions. The authors expect 2026 deal value to strengthen modestly with stable-to-improving volumes, supported by easing inflation, stabilising interest rates and improved financing conditions. Activity will likely remain below prior peaks on a volume basis, with large deals and consolidation continuing to drive aggregate value.
Several structural factors underpin these expectations. Surging electricity demand from AI, data centres and electrification is catalysing acquisitions of generation, grid and midstream assets and supporting higher valuations for scalable infrastructure. Private equity and strategic consortiums are accelerating capital deployment, particularly in assets tied to energy security, reliability and transition themes. Portfolio consolidation remains central in oil and gas and utilities, as companies pursue scale and high-quality resource positions amidst commodity volatility.
Policy and geopolitical uncertainty, including shifting domestic energy policy and global supply risks, are constraining mid-market activity and reinforcing the shift towards larger, de-risked transactions. Overall, the authors expect a disciplined but active M&A environment in 2026, with total deal value supported by large-scale transactions and infrastructure investment while transaction counts recover gradually.
Aerospace and defence
The outlook for M&A in the aerospace and defence sector in 2026 is strong, with expected acceleration in consolidation. The sector is positioned for strategic growth, driven by shifting national security priorities and accelerating innovation cycles. M&A has become a primary growth lever as buyers target assets that accelerate modernisation. Key drivers include:
Deal activity has shown strong growth so far in 2026, with deal value up approximately 119% year-over-year and volume up about 67%. Strategic buyers are focusing on defence electronics, cyber capabilities, space and satellite technologies, and advanced manufacturing and propulsion.
Major corporations are divesting underperforming assets to redeploy capital into defence tech, munitions and space, with proceeds from more than USD15 billion in global transactions being reinvested into high-growth segments. Private equity funds are deploying record capital into carve-outs and mid-tier defence suppliers, building scalable technology platforms for both military and civilian use. The M&A market for aerospace and defence is expected to grow from USD27.22 billion in 2025 to USD38.51 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 3.53%.
Pharmaceuticals and life sciences
The pharmaceutical and life sciences sector enters 2026 with confidence and ample capital following a strong second half of 2025. M&A activity accelerated sharply in 2025, marking one of the busiest years on record.
Key drivers include patent expiries for major drugs, the need for innovation in biotech, gene therapy and precision medicine, and the desire for external pipeline acquisition as R&D productivity pressures persist. Companies face an average of USD47 billion in global pharmaceutical revenue being at risk annually over the next four years due to patent cliff pressures, driving urgency for pipeline replenishment through acquisitions.
Typical acquisition targets include small and mid-size biotech firms and novel therapeutic platforms such as cell and gene therapies, antibody-drug conjugates and AI-enabled drug discovery. Oncology, radiopharmaceuticals, cardio-metabolic conditions, CNS/neuroscience and immunology remain at the forefront of M&A activity. Companies are prioritising bolt-on acquisitions and contingent value rights to bridge valuation gaps. The industry has an estimated USD2.1 trillion in available firepower, with deal making expected to continue accelerating through 2026.
Real estate
Real estate M&A is expected to regain momentum in 2026 as pricing clarity improves and investors shift from defensive positioning to selective deployment. The overall outlook is a gradual recovery, driven by stabilising interest rates improving financing conditions, distressed asset opportunities after the commercial real estate downturn, and institutional capital returning to the sector.
Public-to-private REIT transactions and market consolidation are expected to accelerate as companies pursue scale and strategic asset repositioning. Global capital is reallocating away from traditional real estate assets such as office and retail towards infrastructure-adjacent assets, including data centres, logistics networks and residential-oriented properties. Data centres remain the top prospect for investment in 2026.
Global real estate investment is forecast to increase by 15% in 2026, with deal values through the first nine months of 2025 already up 6% year over year. Technology adoption is becoming critical, with 53% of real estate CEOs indicating a clearly defined roadmap for AI initiatives. Private equity funds and institutional investors are expected to drive deal activity, especially in the middle market, as firms increasingly use acquisitions to expand capital markets capabilities and geographic presence.
2311 Highland Avenue South
Suite 500
Birmingham, Alabama 35205
USA
+1 205 930 5100
+1 205 930 5101
marketing.us.dsp@dentons.com www.dentons.com